Post-malarial anemia in Mozambican children treated with quinine or artesunate: A retrospective observational study

Malaria remains one of the most important global parasitic diseases, causing 219 million cases and around 435 000 deaths in 2017 (WHO, 2019). This overwhelming burden makes the optimal management of malaria a global health priority. In terms of curative efficacy, parenteral artesunate is undoubtedly superior to quinine (Dondorp et al., 2005, 2010), and thus is currently recommended globally as the standard of care for the treatment of severe malaria. Meta-analyses have also confirmed that artesunate has a better short-term safety profile than quinine (Sinclair et al., 2012).
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Source Type: research